S M Belknap

Summary

Affiliation: Northwestern University
Country: USA

Publications

  1. ncbi Quality of methods for assessing and reporting serious adverse events in clinical trials of cancer drugs
    S M Belknap
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Pharmacol Ther 88:231-6. 2010
  2. ncbi Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids
    S M Belknap
    Division of General Internal Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Pharmacol Ther 84:385-92. 2008
  3. ncbi Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project
    Steven M Belknap
    Division of General Internal Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Cancer 106:2051-7. 2006
  4. ncbi Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
    A M Evens
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Ann Oncol 22:1170-80. 2011
  5. ncbi Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers
    Charles L Bennett
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Arch Intern Med 167:1041-9. 2007
  6. ncbi Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, VA Chicago Healthcare System, Chicago, IL, USA
    Blood 106:3343-7. 2005
  7. ncbi The Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    Jesse Brown VA Medical Center Mid West Center for Health Services and Policy Research, Chicago, Ill 60611, USA
    JAMA 293:2131-40. 2005
  8. ncbi Pure red-cell aplasia and epoetin therapy
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
    N Engl J Med 351:1403-8. 2004
  9. ncbi Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project
    Lisa A Ladewski
    Veterans Affairs Midwest Center for Health and Policy Research, Lakeside Division, Northwestern University Medical Center, Chicago, IL 60611, USA
    J Clin Oncol 21:3859-66. 2003
  10. ncbi Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals
    Shilpa M Patel
    Veterans Affairs Chicago Healthcare System/Lakeside Division, Chicago, IL, USA
    J Acquir Immune Defic Syndr 35:120-5. 2004

Collaborators

Detail Information

Publications11

  1. ncbi Quality of methods for assessing and reporting serious adverse events in clinical trials of cancer drugs
    S M Belknap
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Pharmacol Ther 88:231-6. 2010
    ..The use of a validated tool to describe and assess event type, severity, and causality may lead to more timely, accurate identification of safety signals in cancer treatment...
  2. ncbi Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids
    S M Belknap
    Division of General Internal Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
    Clin Pharmacol Ther 84:385-92. 2008
    ..2.7%, number needed to treat (NNT) = 35, P < 0.015). The widespread diffusion of POPA was associated with a substantial hospitalwide decline in opioid-associated severe/fatal ADEs...
  3. ncbi Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project
    Steven M Belknap
    Division of General Internal Medicine, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Cancer 106:2051-7. 2006
    ....
  4. ncbi Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports
    A M Evens
    Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
    Ann Oncol 22:1170-80. 2011
    ..Rituximab has been associated with hepatitis B virus reactivation (HBV-R). However, the characteristics and scope of this association remain largely undefined...
  5. ncbi Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers
    Charles L Bennett
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Arch Intern Med 167:1041-9. 2007
    ..We compare safety efforts for evaluating serious ADRs conducted by the FDA and pharmaceutical manufacturers vs the RADAR project...
  6. ncbi Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, VA Chicago Healthcare System, Chicago, IL, USA
    Blood 106:3343-7. 2005
    ..Reinitiation of epoetin therapy among individuals could be considered if antierythropoietin antibodies are undetectable...
  7. ncbi The Research on Adverse Drug Events and Reports (RADAR) project
    Charles L Bennett
    Jesse Brown VA Medical Center Mid West Center for Health Services and Policy Research, Chicago, Ill 60611, USA
    JAMA 293:2131-40. 2005
    ....
  8. ncbi Pure red-cell aplasia and epoetin therapy
    Charles L Bennett
    MidWest Center for Health Services Research and Policy Studies, Jesse Brown Veterans Affairs Medical Center, Chicago, IL 60611, USA
    N Engl J Med 351:1403-8. 2004
    ....
  9. ncbi Dissemination of information on potentially fatal adverse drug reactions for cancer drugs from 2000 to 2002: first results from the research on adverse drug events and reports project
    Lisa A Ladewski
    Veterans Affairs Midwest Center for Health and Policy Research, Lakeside Division, Northwestern University Medical Center, Chicago, IL 60611, USA
    J Clin Oncol 21:3859-66. 2003
    ..This suggests a need for continued vigilance and efficient strategies for dissemination of information about ADRs associated with cancer drugs...
  10. ncbi Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals
    Shilpa M Patel
    Veterans Affairs Chicago Healthcare System/Lakeside Division, Chicago, IL, USA
    J Acquir Immune Defic Syndr 35:120-5. 2004
    ..The rate of severe hepatotoxicity appears to be greater in non-HIV-infected individuals than in HIV-infected persons and may be associated with higher CD4 counts. The use of PEP regimens containing nevirapine should be discouraged...
  11. ncbi Adverse drug events in emergency department patients
    John W Hafner
    Department of Emergency Medicine, OSF Saint Francis Medical Center, Peoria, IL 61637, USA
    Ann Emerg Med 39:258-67. 2002
    ..Less is known about this common type of injury in emergency department patients. This study seeks to measure the risks, incidence, severity, and costs of ADEs in an ED population...